Skip to main content

Use of Selective Serotonin Reuptake Inhibitors (SSRIs) in Women Delivering Liveborn Infants and other Women of Child-Bearing Age within the U.S. Food and Drug Administration's Mini-Sentinel Program

Basic Details
Date
Friday, May 13, 2016
Type
Publication
Medical Product
selective serotonin reuptake inhibitor (SSRI)
Health Outcome(s)
birth
pregnancy
Description

This study was conducted in order to assess the prevalence of use of selective serotonin reuptake inhibitors (SSRIs) among pregnant women delivering a liveborn infant in the USA.

Materials

Archives of Women's Mental Health; Volume 19, Issue 6, 13 May 2016, Pages 699-977. DOI:10.1007/s00737-016-0637-1

Author(s)

Susan E. Andrade ScD, Marsha E. Reichman PhD, Katrina Mott MS, Marilyn Pitts PharmD, Caren Kieswetter MD, MPH, Miriam Dinatale DO, Marc B. Stone MD, Jennifer Popovic DVM, MA, Katherine Haffenreffer BS, Sengwee Toh ScD

Corresponding Author

S. Andrade, Meyers Primary Care Institute (Fallon Community Health Plan, Reliant Medical Group, and University of Massachusetts Medical School), Worcester, USA. Email: sandrade@meyersprimary.org